-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: Not applicable.
References
1. Ferraro, S, Biganzoli, EM. The clinical value of assessing the inter-method bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med 2022;60:149–51.10.1515/cclm-2021-1125Search in Google Scholar PubMed
2. AACC Artery. Free prostate specific antigen. Available from: https://artery.aacc.org/communities/community-home/digestviewer/viewthread?GroupId=7&MessageKey=fd73002b-a04e-4c73-a888-9916244ae6e3&CommunityKey=723b6334-7f7c-4ed0-bc02-e38d42226ed7&tab=digestviewer&ReturnUrl=%2fcommunities%2fcommunity-home%2fdigestviewer%3ftab%3ddigestviewer%26CommunityKey%3d723b6334-7f7c-4ed0-bc02-e38d42226ed7 [Accessed 8 Feb 2022].Search in Google Scholar
3. Huang, HQ, Zhang, Y, Xu, HG. Different free prostate-specific antigen to total prostate-specific antigen ratios using three detecting systems. J Clin Lab Anal 2018;32:e22231. https://doi.org/10.1002/jcla.22231.Search in Google Scholar
4. Van Duijnhoven, HL, Péquériaux, NC, Van Zon, JP, Blankenstein, MA. Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient. Clin Chem 1996;42:637–41. https://doi.org/10.1093/clinchem/42.4.637.Search in Google Scholar
5. Park, S, Wians, FHJr, Cadeddu, JA. Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies. Int J Urol 2007;14:251–3. https://doi.org/10.1111/j.1442-2042.2006.01648.x.Search in Google Scholar
6. Pedrosa, W, Teixeira, L. Interference of heterophilic antibodies with free prostate-specific antigen in the Beckman-Coulter (Unicel DxI) assay, inverting the free/total prostate-specific antigen ratio. Ann Clin Biochem 2009;46:344–5. https://doi.org/10.1258/acb.2009.008242.Search in Google Scholar
7. Cavalier, E. Aberrant results observed with four immuno-assays for total and free prostate-specific antigen (PSA) determination: a case-report. Clin Chem Lab Med 2011;50:583–4. https://doi.org/10.1515/CCLM.2011.807.Search in Google Scholar
8. Jung, K, Stephan, C, Lein, M. Assay-dependent abnormalities in measurements of prostate-specific antigen in serum: an occasional occurrence, but of clinical significance. Clin Chem Lab Med 2012;50:585–6. https://doi.org/10.1515/cclm.2011.843.Search in Google Scholar
9. Lautenbach, N, Müntener, M, Zanoni, P, Saleh, L, Saba, K, Umbehr, M, et al.. Prevalence and causes of abnormal PSA recovery. Clin Chem Lab Med 2018;56:341–9. https://doi.org/10.1515/cclm-2017-0246.Search in Google Scholar
10. Ferraro, S, Bussetti, M, Rizzardi, S, Braga, F, Panteghini, M. Verification of harmonization of serum total and free prostate-specific antigen (PSA) measurements and implications for medical decisions. Clin Chem 2021;67:543–53. https://doi.org/10.1093/clinchem/hvaa268.Search in Google Scholar
11. Ferraro, S, Bussetti, M, Bassani, N, Rossi, RS, Incarbone, GP, Bianchi, F, et al.. Definition of outcome-based prostate-specific antigen (PSA) thresholds for advanced prostate cancer risk prediction. Cancers 2021;13:3381–95. https://doi.org/10.3390/cancers13143381.Search in Google Scholar
12. Kavsak, PA, Hotte, SJ. A large number of fresh samples and a wide range of total prostate-specific antigen (tPSA) concentrations is important to detect differences in PSA methods. Clin Chem 2021;67:1155–7. https://doi.org/10.1093/clinchem/hvab104.Search in Google Scholar
© 2022 Walter de Gruyter GmbH, Berlin/Boston
